Literature DB >> 19946784

Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study.

Yaroslav Winter1, Sonja von Campenhausen, Julia Gasser, Klaus Seppi, Jens-P Reese, Karl-P Pfeiffer, Kai Bötzel, Wolfgang H Oertel, Richard Dodel, Werner Poewe.   

Abstract

Parkinson's disease (PD) is associated with a reduction of health-related quality of life (HrQoL). Demographic and clinical determinants of HrQoL in PD have been previously investigated, but less is known about its social determinants. Data on HrQoL in Austrian patients with PD are not available. The objective of this cross-sectional survey was to evaluate HrQoL of Austrian patients with PD and to provide a comprehensive analysis of its social and clinical determinants. Outpatients (n = 100) with idiopathic PD were recruited in the Department of Neurology of the University Innsbruck. Clinical status was estimated using the Unified Parkison's Disease Rating Scale (UPDRS). HrQoL was evaluated using a generic instrument, the EuroQol (EQ5D and EQ-VAS). Independent determinants of HrQoL were assessed in multivariate regression analysis. The proportion of PD patients with moderate or severe problems in at least one dimension of the EQ5D was significantly higher than in the general population (90.1 vs. 35.1%, P < 0.001). The mean EQ-VAS score in PD was lower than in the general population (48.9 +/- 19.6 vs. 77.0 +/- 20.8, P < 0.001). Social support (number of household members) was identified as an independent social determinant of HrQoL. Demographic and clinical determinants were age, depression, UPDRS and motor fluctuations. The analysis of determinants of HrQoL showed that a greater attention should be paid to social support and home care. Our data on HrQoL in PD should be considered in the development of new health care programs.

Entities:  

Mesh:

Year:  2009        PMID: 19946784     DOI: 10.1007/s00415-009-5389-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Cost of disorders of the brain in Europe.

Authors:  Patrik Andlin-Sobocki; Bengt Jönsson; Hans-Ulrich Wittchen; Jes Olesen
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

3.  Cost of Parkinson's disease in Europe.

Authors:  P Lindgren; S von Campenhausen; Ea Spottke; U Siebert; R Dodel
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

4.  Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

Authors:  M Péchevis; C E Clarke; P Vieregge; B Khoshnood; C Deschaseaux-Voinet; G Berdeaux; M Ziegler
Journal:  Eur J Neurol       Date:  2005-12       Impact factor: 6.089

5.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

Authors:  J Brazier; N Jones; P Kind
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

6.  Health-related quality of life and sleep disorders in Parkinson's disease.

Authors:  T Scaravilli; E Gasparoli; F Rinaldi; G Polesello; F Bracco
Journal:  Neurol Sci       Date:  2003-10       Impact factor: 3.307

7.  The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease.

Authors:  V Peto; C Jenkinson; R Fitzpatrick; R Greenhall
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

8.  Development and testing of the Parkinson's disease quality of life scale.

Authors:  Mickie Welsh; Michael P McDermott; Robert G Holloway; Sandy Plumb; Ronald Pfeiffer; Jean Hubble
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

9.  Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial.

Authors:  Connie Marras; Michael P McDermott; Paula A Rochon; Caroline M Tanner; Gary Naglie; Anthony E Lang
Journal:  Mov Disord       Date:  2008-04-15       Impact factor: 10.338

10.  Determinants of quality of life in Brazilian patients with Parkinson's disease.

Authors:  Francisco Javier Carod-Artal; Antonio Pedro Vargas; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

View more
  20 in total

1.  Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis.

Authors:  Bruno Kusznir Vitturi; Alexandre In Han Kim; Lucas Pari Mitre; Ada Pellegrinelli; Berenice Cataldo Oliveira Valerio
Journal:  Neurol Sci       Date:  2020-06-26       Impact factor: 3.307

2.  Concordance between severity of disease, prevalence of nonmotor symptoms, patient-reported quality of life and disability and use of medication in Parkinson's disease.

Authors:  Alberto Raggi; Matilde Leonardi; Venusia Covelli; Alberto Albanese; Paola Soliveri; Francesco Carella; Luigi Romito
Journal:  Neurol Sci       Date:  2011-11-10       Impact factor: 3.307

3.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

4.  How parkinsonism influences life: the patients' point of view.

Authors:  E Martignoni; Antonietta Citterio; R Zangaglia; L Godi; C Pacchetti; C Fundarò; E Corengia; G Bono; G Nappi
Journal:  Neurol Sci       Date:  2010-11-06       Impact factor: 3.307

5.  Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Yaroslav Winter; Karsten Schepelmann; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Björn Tackenberg; Veit Mylius; Jens-Peter Reese; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 6.  Assessment of the construct validity and responsiveness of preference-based quality of life measures in people with Parkinson's: a systematic review.

Authors:  Yiqiao Xin; Emma McIntosh
Journal:  Qual Life Res       Date:  2016-10-24       Impact factor: 4.147

7.  Mapping of the PDQ-39 to EQ-5D scores in patients with Parkinson's disease.

Authors:  Megan K Young; Shu-Kay Ng; George Mellick; Paul A Scuffham
Journal:  Qual Life Res       Date:  2012-07-11       Impact factor: 4.147

8.  Essential gains and health after upper-limb tetraplegia surgery identified by the International classification of functioning, disability and health (ICF).

Authors:  L Bunketorp-Käll; C Reinholdt; J Fridén; J Wangdell
Journal:  Spinal Cord       Date:  2017-04-18       Impact factor: 2.772

9.  EQ-5D studies in nervous system diseases in eight Central and East European countries: a systematic literature review.

Authors:  Valentina Prevolnik Rupel; Marko Divjak; Zsombor Zrubka; Fanni Rencz; László Gulácsi; Dominik Golicki; Dagmara Mirowska-Guzel; Judit Simon; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek
Journal:  Eur J Health Econ       Date:  2019-05-16

Review 10.  Understanding, Impact, and Communication of "Off" Periods in Parkinson's Disease: A Scoping Review.

Authors:  Tara Rastgardani; Melissa J Armstrong; Anna R Gagliardi; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2018-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.